PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Zhong YM, Yin K, Chen Y, Xie Z, Lv ZY, Yang JJ, Yang XN, Zhou Q, Wang BC, Zhong WZ, Gao LL, Zhou WB, Chen J, Tu HY, Liao RQ, Zhang DK, Zhang SL, Lu DX, Zheng HB, Zhang HH, Wu YL, Zhang XC.
Zhong YM, et al. Among authors: zhou wb, zhou q.
Front Immunol. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817. eCollection 2022.
Front Immunol. 2022.
PMID: 36263036
Free PMC article.